Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Vekemans

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1993
Characterization of gastric antral motility disturbances in diabetes using a scintigraphic techniqueJ L Urbain, M C Vekemans, R Bouillon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1995
Dynamic antral scintigraphy to characterize gastric antral motility in functional dyspepsiaJ L Urbain, M C Vekemans, H Parkman, et al.
Leukemia|August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterR B Walter, M Othus, A K Burnett, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica|October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myelomaR Schots, M Delforge, M André, et al.
Journal of Internal Medicine|December 8, 2017
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemiaC Craddock, J Versluis, M Labopin, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia|February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1993
Characterization of gastric antral motility disturbances in diabetes using a scintigraphic techniqueJ L Urbain, M C Vekemans, R Bouillon, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1995
Dynamic antral scintigraphy to characterize gastric antral motility in functional dyspepsiaJ L Urbain, M C Vekemans, H Parkman, et al.
Leukemia|August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterR B Walter, M Othus, A K Burnett, et al.
Acta Clinica Belgica|December 8, 2011
Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in BelgiumM Delforge, A Michiels, C Doyen, et al.
Acta Clinica Belgica|October 20, 2010
The Belgian 2010 consensus recommendations for the treatment of multiple myelomaR Schots, M Delforge, M André, et al.
Journal of Internal Medicine|December 8, 2017
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemiaC Craddock, J Versluis, M Labopin, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Leukemia|February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Pageof 2